NCT06630247 - A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

May 7, 2025

Study Completion Date

May 7, 2025

Conditions

Solid CancersSolid Tumor CancerSolid Tumor MalignancyUrothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)Metastatic Solid TumorLocally Advanced Solid TumorUrothelial Cancer of Renal Pelvis

Interventions

DRUG

XL495

oral doses of XL495

DRUG

ADC cytotoxic agents

intravenous infusion of anti-cancer combination agent

Trial Locations (10)

10029

Exelixis Clinical Site #7, New York

20007

Exelixis Clinical Site #8, Washington D.C.

28078

Exelixis Clinical SIte #2, Huntersville

37203

Exelixis Clinical Site #3, Nashville

Exelixis Clinical Site #5, Nashville

70121

Exelixis Clinical Site #10, Jefferson

77030

Exelixis Clinical Site #6, Houston

78758

Exelixis Clinical Site #1, Austin

80218

Exelixis Clinical Site #4, Denver

06511

Exelixis Clinical Site #9, New Haven